Is EVLO or SBUX a better dividend investment in 2026?

EVLO currently yields 2000000.00% with a 5% 5-year dividend growth rate. SBUX yields 2.75% with 5% growth. The better choice depends on your goal: EVLO offers higher current income.

What is the dividend yield difference between EVLO and SBUX?

EVLO has a forward dividend yield of 2000000.00% ($2.00/share annually). SBUX yields 2.75% ($2.46/share annually). The yield gap is 1999997.25 percentage points.

Home › Compare › EVLO vs SBUX

EVLO vs SBUX: Dividend Comparison 2026

EVLO yields 2000000.00% · SBUX yields 2.75%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EVLO wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EVLO

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full EVLO calculator →

SBUX

● Live price

2.75%

Share price

$89.59

Annual div

$2.46

5Y div CAGR

48.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$157.5K

Annual income

$65,840.13

Full SBUX calculator →

Portfolio growth — EVLO vs SBUX

📍 EVLO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EVLO	SBUX
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EVLO + SBUX cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EVLO pays

SBUX pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVLO

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

SBUX

Annual income on $10K today (after 15% tax)

$233.40/yr

After 10yr DRIP, annual income (after tax)

$55,964.11/yr

At 15% tax rate, EVLO beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVLO + SBUX for your $10,000?

EVLO: 50%SBUX: 50%

100% SBUX50/50100% EVLO

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

EVLO

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-53.3

Piotroski

3/9

SBUX

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$104.00

+16.1% upside vs current

Range: $90.00 — $120.00

Altman Z

2.6

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVLO buys

SBUX buys

No recent congressional trades found for EVLO or SBUX in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEVLOSBUX

Forward yield	2000000.00% ✓	2.75%
Annual dividend / share	$2.00	$2.46 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	48.3% ✓
Portfolio after 10y	$4.879226400974806e+39M	$157.5K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$65,840.13
Total dividends collected	$4.879195005460081e+39M	$127.5K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Discretionary
Analyst consensus	Buy	Buy

Year-by-year: EVLO vs SBUX ($10,000, DRIP)

Year	EVLO Portfolio	EVLO Income/yr	SBUX Portfolio	SBUX Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,107	$407.21	+$200.00M → EVLO
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,512	$626.87	+$3738731.76M → EVLO
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$14,366	$978.69	+$65315062866.92M → EVLO
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$16,929	$1,557.50	+$1066400830062625.00M → EVLO
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$20,658	$2,543.80	+$16272182796453826560.00M → EVLO
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$26,406	$4,302.22	+$2.3205424011366188e+23M → EVLO
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$35,877	$7,622.00	+$3.0927990661046884e+27M → EVLO
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$52,741	$14,352.64	+$3.8524105697352695e+31M → EVLO
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$85,676	$29,243.03	+$4.484688260147987e+35M → EVLO
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$157,513	$65,840.13	+$4.879226400974806e+39M → EVLO

EVLO vs SBUX: Complete Analysis 2026

EVLO — Stock

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Full EVLO Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →

📬

Get this EVLO vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVLO vs SCHD EVLO vs JEPI EVLO vs O EVLO vs KO EVLO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.